Alterity Therapeutics Ltd. (PRNAF)
OTHER OTC:PRNAF
Want to see PRNAF full AI Analyst Report?
PRNAF Stock Chart & Stats
$0.01
>-$0.01(-47.06%)
At close: 4:00 PM EDT
$0.01
>-$0.01(-47.06%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume10.00K
Average Volume (3M)36.00
Market Cap
$70.25M
Enterprise Value$59.72M
Total Cash (Recent Filing)$49.20M
Total Debt (Recent Filing)$163.91K
Price to Earnings (P/E)―
Beta5.20
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding10,875,416,000
10 Day Avg. Volume0
30 Day Avg. Volume36
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue15.58
Enterprise Value/Gross Profit16.09
Enterprise Value/Ebitda-2.97
Forecast
1Y Price Target
<$0.01Price Target Upside-28.25% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$3.82M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal financial leverage reduces bankruptcy and interest-rate risk, giving management flexibility to prioritize R&D and clinical programs. Over 2-6 months this supports runway extension options and lowers fixed financing costs versus more leveraged peers, preserving strategic optionality.
Healthy Equity BaseA healthy equity base strengthens the balance sheet, supporting continued investment in clinical development without immediate solvency pressure. This structural capital cushion improves credibility with partners and regulators and reduces near-term liquidity fragility as trials progress.
Strong Revenue GrowthRobust top-line expansion signals increasing non‑operating or collaboration income or milestone receipts that can de-risk programs and fund development. Sustained revenue growth over months improves funding diversity and supports a longer development runway versus flat or declining receipts.
Bears Say
Negative ProfitabilityPersistently negative operating and net margins indicate the company cannot yet generate profits from its activities, necessitating continued external funding. Over a multi-month horizon this reduces internal self-funding capacity and increases execution risk if capital markets tighten.
Weak Cash GenerationNegative and declining cash flows point to inefficient conversion of resources into liquidity, shortening the practical runway for clinical programs. This structural cash deficit typically forces repeated equity raises or dilutive financings, complicating long-term planning and partner negotiations.
Dependence On External FundingAs a clinical‑stage biotech without commercial products, the business relies on equity raises, grants, or partnerships to fund R&D. This structural dependence increases dilution and timing risk, and makes program continuity sensitive to capital markets and partner appetite over the coming months.
Alterity Therapeutics News
PRNAF FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is $70.25M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 318 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported >-$0.001 earnings per share for the quarter, the consensus estimate of >-$0.001 by $0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of >-$0.001 in its last earnings report, expectations of >-$0.001. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in PRNAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
<$0.01 (-28.25% Downside)
<$0.01 (-28.25% Downside)
Blogger Sentiment
Bullish
PRNAF Sentiment 95%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
PRNAF Stock 12 Month Forecast
Average Price Target
<$0.01
▼(-28.25% Downside)
Technical Analysis
Actinogen Medical
―
Cynata Therapeutics Limited
―
Tryptamine Therapeutics
―
Living Cell Technologies
―
Neuren Pharmaceuticals Limited
―
Ownership Overview
0.21%
Insiders
― Other Institutional Investors
99.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---